News
01-10-2013, 10:20 PM
TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.
More... (http://www.news-medical.net/news/20130111/TapImmune-announces-results-from-HER2neu-interim-study-on-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130111/TapImmune-announces-results-from-HER2neu-interim-study-on-breast-cancer.aspx)